Drugs / DW1903
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05155072 | May → Sep 2020 | gastritis | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05163756 | Nov 2020 → Apr 2021 | chronic gastritis | Daewon Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW1903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05163756 ↗ |
| Known as | esomeprazole | “randomly assigned 476 patients with endoscopic erosive gastritis to a group using esomeprazole 10 mg (DW1903) daily and a group using famotidine 20 mg (DW1903R1) daily for 2 weeks.” PMID 37309193 ↗ Jun 2023 |
| Route | Oral | “After Oral Administration of DW1903, DW1903-R1 and DW1903-R2” NCT05155072 ↗ |